ORIGINAL RESEARCH—PEYRONIE'S DISEASEORIGINAL RESEARCH—PEYRONIE’S DISEASE: Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie’s Disease— A Placebo-Controlled Pilot Study

Introduction Transdermal and intralesional verapamil has been reported to be useful in the treatment of Peyronie’s Disease. This study evaluates a topically applied calcium channel blocker (verapamil hydrochloride 15% gel), a topically applied calmodulin blocker (trifluoperazine), and a topically applied weak calcium channel blocker (magnesium sulfate), each incorporated in a transdermal vehicle.